iSpeak Blog

Keynote Speakers Announced for 2018 ISPE Aseptic Conference

Article

ISPE announced its full technical program and keynote speakers for the 2018 ISPE Aseptic Conference taking place 6 - 7 March in Reston, Virginia. The following keynote addresses will showcase industry leaders offering compelling and enlightening presentations in their own respected areas of aseptic processing.

Keynote Speakers

Joyce M. Hansen
Vice President of J&J Microbiological Quality and Sterility Assurance
Johnson & Johnson

Joyce M. Hansen is currently Vice President of Sterility Assurance for Johnson & Johnson. Her presentation will focus on a call to industry to act as change agents in addressing the challenge of legacy facilities and creating a vision to upgrade them. With 38 years of experience, she is a recognized industry leader in sterility assurance and sterilization practices. Prior to joining Johnson & Johnson, Joyce was the President and Founder of the consulting firm J.M. Hansen & Associates, Inc.

Robert Sausville
Director, Division of Case Management
FDA/CBER/OMPT/OCBQ

Robert Sausville is Director, Division of Case Management (DCM) Office of Compliance and Biologics Quality, at FDA’s Center for Biologics Evaluation and Research (CBER). Robert’s session will provide a unique FDA perspective informed by thirty years of industry experience and observations in aseptic processing. Prior to joining DCM, Sausville spent eight years in CBER’s Division of Manufacturing and Product Quality where his responsibilities included review of establishment and biologics license applications and supplements related to viral vaccines, monoclonal antibodies, in-vitro diagnostic kits, and plasma fractionation products.

The 2018 ISPE Aseptic Conference remains at the forefront of education in the evolution of aseptic technology, featuring content-rich sessions and an exhibit hall with the latest innovations in aseptic processing. The 2018 ISPE Aseptic Conference will address challenges in the field, including innovation for the future, upgrading legacy facilities, and containment issues with highly potent and toxic products.

Register Today